Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by davewhoon Apr 03, 2021 4:47pm
133 Views
Post# 32934240

RE:RE:RE:RE:RE:RE:RE:Price on monday

RE:RE:RE:RE:RE:RE:RE:Price on mondayQ1 is on the books now and will be out next month along with the AGM. We should see another good bump up in rev and a get a clearer picture of how the Aristotle plan is unfolding. A few people have wondered if the Q4 delay was intentional. But Szls has a history of messing QR's up so probably not a viable theory. I agree if things had happened in a different order Thursday may never have been a problem. Q4 a couple days early showing the $2.8m, a CC highlighting increasing rev and Aristotle shortly. Then Care Oncology NR this coming week. Whole different out come? Probably. But in reality we are still the same company with the same huge potential we always had. 
<< Previous
Bullboard Posts
Next >>